GeneDx Holdings (WGS) Change in Accured Expenses (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Change in Accured Expenses data on file, last reported at -$13.2 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$13.2 million, down 221.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.9 million (down 139.42% YoY), and the FY2025 annual result was $12.1 million, up 158.96% from the prior year.
• Change in Accured Expenses fell to -$13.2 million in Q1 2026 per WGS's latest filing, from $6.9 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $42.3 million in Q2 2022 and troughed at -$14.5 million in Q3 2023.
• A 5-year average of -$2.1 million and a median of -$6.1 million in 2024 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 459.2% in 2022 and fell as far as 266.64% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at $5.9 million in 2022, then slumped by 256.79% to -$9.3 million in 2023, then slumped by 37.42% to -$12.7 million in 2024, then jumped by 154.38% to $6.9 million in 2025, then slumped by 290.43% to -$13.2 million in 2026.
• Business Quant data shows WGS's Change in Accured Expenses at -$13.2 million in Q1 2026, $6.9 million in Q4 2025, and -$2.0 million in Q3 2025.